Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by XTX Topco Ltd

Key Points

• XTX Topco Ltd increased its stake in Gilead Sciences by 76.8%, acquiring a total of 9,156 shares valued at approximately $1,026,000.
• Insider Johanna Mercier and Director Jeffrey Bluestone sold a total of 8,000 shares of Gilead Sciences stock, with insiders having sold 82,000 shares worth nearly $9 million over the past 90 days.
• Gilead's stock opened at $113.18 and has seen analysts assign an average rating of "Moderate Buy" with a consensus target price of $112.36.

XTX Topco Ltd boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 76.8% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 9,156 shares of the biopharmaceutical company's stock after purchasing an additional 3,976 shares during the period. XTX Topco Ltd's holdings in Gilead Sciences were worth $1,026,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of GILD. Bridgewater Associates LP grew its holdings in shares of Gilead Sciences by 122.7% during the fourth quarter. Bridgewater Associates LP now owns 460,936 shares of the biopharmaceutical company's stock valued at $42,577,000 after buying an additional 253,994 shares during the last quarter. Nissay Asset Management Corp Japan ADV lifted its position in Gilead Sciences by 5.2% during the 4th quarter. Nissay Asset Management Corp Japan ADV now owns 284,243 shares of the biopharmaceutical company's stock worth $26,750,000 after acquiring an additional 14,009 shares during the period. Golden State Wealth Management LLC grew its stake in Gilead Sciences by 14.5% during the 1st quarter. Golden State Wealth Management LLC now owns 863 shares of the biopharmaceutical company's stock valued at $97,000 after purchasing an additional 109 shares during the last quarter. Ontario Teachers Pension Plan Board increased its holdings in shares of Gilead Sciences by 54.6% in the fourth quarter. Ontario Teachers Pension Plan Board now owns 37,051 shares of the biopharmaceutical company's stock valued at $3,422,000 after purchasing an additional 13,086 shares during the period. Finally, Mufg Securities Americas Inc. purchased a new position in shares of Gilead Sciences in the fourth quarter worth about $1,699,000. Institutional investors and hedge funds own 83.67% of the company's stock.

Insider Activity at Gilead Sciences

In related news, insider Johanna Mercier sold 3,000 shares of the business's stock in a transaction on Tuesday, July 15th. The shares were sold at an average price of $111.03, for a total value of $333,090.00. Following the completion of the sale, the insider owned 117,168 shares of the company's stock, valued at approximately $13,009,163.04. The trade was a 2.50% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction on Monday, July 14th. The shares were sold at an average price of $109.74, for a total transaction of $548,700.00. Following the transaction, the director directly owned 8,920 shares in the company, valued at approximately $978,880.80. The trade was a 35.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 82,000 shares of company stock worth $8,984,175 over the last 90 days. 0.27% of the stock is owned by insiders.

Gilead Sciences Stock Up 0.8%

Shares of GILD opened at $113.18 on Friday. The firm has a market cap of $140.79 billion, a P/E ratio of 23.83, a PEG ratio of 0.71 and a beta of 0.33. Gilead Sciences, Inc. has a 12 month low of $72.43 and a 12 month high of $119.96. The stock's 50 day moving average is $110.51 and its two-hundred day moving average is $106.80. The company has a current ratio of 1.37, a quick ratio of 1.23 and a debt-to-equity ratio of 1.16.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Cantor Fitzgerald assumed coverage on Gilead Sciences in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 target price on the stock. Needham & Company LLC raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price objective on the stock in a report on Friday, July 25th. Morgan Stanley increased their price objective on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research note on Friday, April 25th. Finally, Oppenheimer reduced their target price on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a report on Friday, April 25th. Eight analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $112.36.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.